Brief: Bellus Health Announces First Patient Dosed In Its Phase 2 Blueprint Trial Of Blu-5937
14/12/2020 12:02
Dec 14 (Reuters) - BELLUS Health Inc BLU.TO :
* BELLUS HEALTH ANNOUNCES FIRST PATIENT DOSED IN ITS PHASE 2
BLUEPRINT TRIAL OF BLU-5937 FOR TREATMENT OF CHRONIC PRURITUS
ASSOCIATED WITH ATOPIC DERMATITIS
* TOPLINE RESULTS FROM PHASE 2 TRIAL EXPECTED IN Q4 2021
Source text for Eikon: ID:nBw5xnDMQa
Further company coverage: BLU.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BELLUS Health
See all newsBrief: Bellus Health Inc. Calls Special Shareholders’ Meeting In Connection With Gsk Acquisition
Brief: Bellus Health Reports First Quarter 2023 Financial Results And Business Highlights
Press Digest: British Business - April 19
Canada Stocks: Toronto market extends winning streak on 'soft landing' hopes
Bellus soars as GSK plans to buy drug developer for $2 bln